CD274 and glioblastoma: Atezolizumab and durvalumab, both anti-PD-L1 antibodies, showed limited clinical benefits in GBM patients, with some exceptions, but the overall efficacy of checkpoint inhibitor monotherapy for GBM remains unsatisfactory [107].